Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables.

Maki KC, Bobotas G, Dicklin MR, Huebner M, Keane WF.

J Clin Lipidol. 2017 Jan - Feb;11(1):102-109. doi: 10.1016/j.jacl.2016.10.010. Epub 2016 Oct 18.

PMID:
28391875
2.

Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis.

Keane WF, Tomassini JE, Neff DR.

J Atheroscler Thromb. 2013;20(2):123-33. Epub 2012 Oct 25. Review.

3.

Lipid abnormalities in patients with chronic kidney disease.

Keane WF, Tomassini JE, Neff DR.

Contrib Nephrol. 2011;171:135-142. doi: 10.1159/000327317. Epub 2011 May 23. Review.

PMID:
21625102
4.

Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.

Tershakovec AM, Keane WF, Zhang Z, Lyle PA, Appel GB, McGill JB, Parving HH, Cooper ME, Shahinfar S, Brenner BM.

Diabetes Care. 2008 Mar;31(3):445-7. Epub 2007 Dec 10.

PMID:
18070995
5.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.

6.

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.

J Am Soc Nephrol. 2007 May;18(5):1540-6. Epub 2007 Apr 4.

7.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D.

J Hypertens. 2007 Apr;25(4):871-6.

PMID:
17351381
8.

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.

PMID:
17009077
9.

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.

PMID:
16761903
10.

Losartan: lessons learned from the RENAAL study.

Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM.

Expert Opin Pharmacother. 2006 Apr;7(5):623-30. Review.

PMID:
16553578
11.

Kidney disease and cardiovascular disease: implications of dyslipidemia.

Keane WF, Lyle PA.

Cardiol Clin. 2005 Aug;23(3):363-72. Review.

PMID:
16084284
12.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.

13.

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program.

El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM; Kidney Early Evaluation Program.

Kidney Int. 2005 Apr;67(4):1483-8.

14.

Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.

Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2005 Jan;(93):S48-51. Review. No abstract available.

PMID:
15663528
15.

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.

16.

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD.

Kidney Int. 2004 Sep;66(3):1131-8.

17.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Circulation. 2004 Aug 24;110(8):921-7. Epub 2004 Aug 9.

PMID:
15302780
18.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

19.

Nephropathy in diabetes.

Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW; American Diabetes Association.

Diabetes Care. 2004 Jan;27 Suppl 1:S79-83. No abstract available.

PMID:
14693934
20.

Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program.

Brown WW, Collins A, Chen SC, King K, Molony D, Gannon MR, Politoski G, Keane WF.

Kidney Int Suppl. 2003 Feb;(83):S50-5. Review.

PMID:
12864875
21.

Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).

Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM.

Am J Kidney Dis. 2003 Jul;42(1):22-35.

PMID:
12830453
22.

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators.

Kidney Int. 2003 Apr;63(4):1499-507.

23.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.

PMID:
12612946
24.

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.

Diabetes Care. 2003 Mar;26(3):683-7.

PMID:
12610022
25.

Diabetic nephropathy.

Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association.

Diabetes Care. 2003 Jan;26 Suppl 1:S94-8. No abstract available.

PMID:
12502629
26.

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S; RENAAL Study Investigators.

J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328-35.

PMID:
11967819
27.

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure.

Nemoto T, Burne MJ, Daniels F, O'Donnell MP, Crosson J, Berens K, Issekutz A, Kasiske BL, Keane WF, Rabb H.

Kidney Int. 2001 Dec;60(6):2205-14.

28.

Metabolic pathogenesis of cardiorenal disease.

Keane WF.

Am J Kidney Dis. 2001 Dec;38(6):1372-5. Review.

PMID:
11728977
29.

The urgent call of albuminuria/proteinuria. Heeding its significance in early detection of kidney disease.

Hebert LA, Spetie DN, Keane WF.

Postgrad Med. 2001 Oct;110(4):79-82, 87-8, 93-6. Review. Erratum in: Postgrad Med 2002 Feb;111(2):23.

PMID:
11675984
30.

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.

Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish.

PMID:
11601117
31.

Proteinuria and cardiovascular disease.

Weinstock Brown W, Keane WF.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S8-S13. Review.

PMID:
11576914
32.

The national epidemic of chronic kidney disease. What we know and what we can do.

Eknoyan G, Levey AS, Levin NW, Keane WF.

Postgrad Med. 2001 Sep;110(3):23-9: quiz 8.

PMID:
11570203
33.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.

34.

A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18.

Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z, Keane WF, Chvatchko Y, Kim SH, Fantuzzi G, Dinarello CA, Rubinstein M.

Cytokine. 2001 Jun 21;14(6):334-42.

PMID:
11497494
35.
36.

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.

Nemoto T, Yokota N, Keane WF, Rabb H.

Kidney Int. 2001 Jan;59(1):246-51.

37.

Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.

Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S; International Society for Peritoneal Dialysis.

Perit Dial Int. 2000 Jul-Aug;20(4):396-411. No abstract available. Erratum in: Perit Dial Int 2000 Nov-Dec;20(6):828-9.

PMID:
11007371
38.

Treatment of peritonitis: update or new course.

Vas SI, Keane WF.

Perit Dial Int. 2000 Jul-Aug;20(4):384-5. No abstract available.

PMID:
11007367
39.

Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.

Sica DA, Halstenson CE, Gehr TW, Keane WF.

Clin Pharmacokinet. 2000 Jun;38(6):519-26.

PMID:
10885588
40.

The role of lipids in renal disease: future challenges.

Keane WF.

Kidney Int Suppl. 2000 Apr;75:S27-31. Review.

PMID:
10828758
41.

Proteinuria: its clinical importance and role in progressive renal disease.

Keane WF.

Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S97-105. Review.

PMID:
10766008
42.

Diabetes in the elderly population.

Khan MA, Collins AJ, Keane WF.

Adv Ren Replace Ther. 2000 Jan;7(1):32-51. Review.

PMID:
10672916
43.

Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.

Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP.

Biochem Biophys Res Commun. 2000 Jan 19;267(2):536-40.

PMID:
10631097
44.

Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.

Keane WF, Swan SK, Grimes I, Humphries TJ.

J Clin Pharmacol. 1999 Sep;39(9):927-33.

PMID:
10471983
45.

Lipids and progressive renal disease: the cardio-renal link.

Keane WF.

Am J Kidney Dis. 1999 Aug;34(2):xliii-xlvi. No abstract available.

PMID:
10465726
46.

Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells.

Oda H, Kasiske BL, O'Donnell MP, Keane WF.

Kidney Int Suppl. 1999 Jul;71:S202-5.

PMID:
10412776
47.

Lipophilic statins induce apoptosis of human vascular smooth muscle cells.

Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Egido J.

Kidney Int Suppl. 1999 Jul;71:S88-91.

PMID:
10412746
48.

Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis.

Massy ZA, Guijarro C, Oda H, Kasiske BL, Keane WF, O'Donnell MP.

Kidney Int Suppl. 1999 Jul;71:S80-3.

PMID:
10412744
49.

The central role of nuclear factor-kappa B in mesangial cell activation.

Massy ZA, Guijarro C, O'Donnell MP, Kim Y, Kashtan CE, Egido J, Kasiske BL, Keane WF.

Kidney Int Suppl. 1999 Jul;71:S76-9. Review.

PMID:
10412743
50.

Recent advances in statins and the kidney.

Oda H, Keane WF.

Kidney Int Suppl. 1999 Jul;71:S2-5. Review.

PMID:
10412725

Supplemental Content

Loading ...
Support Center